on Aspire Biopharma, Inc. (NASDAQ:PWUP)
Aspire Biopharma Names Michael C. Howe as New CEO
Michael C. Howe has been appointed as the new Chief Executive Officer of Aspire Biopharma Holdings, Inc., effective June 10, 2025. Previously serving as an Independent Board Member, Howe brings over four decades of experience from brands like MinuteClinic, Procter & Gamble, PepsiCo, and Arby's. He is known for his strategic leadership and vision in driving transformative growth.
Kraig Higginson, former CEO and Chairman, will continue as Executive Chairman. Aspire, a developer of innovative drug delivery technology, selected Howe for his expertise in scaling differentiated platforms and navigating the health and wellness sector. Higginson expressed confidence in Howe's capacity to lead during a critical time for Aspire.
Howe acknowledges Aspire's promising drug delivery platform and clinical trials anticipated to support an FDA submission. He is committed to enhancing the company’s future and shareholder value.
R. E.
Copyright © 2025 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all Aspire Biopharma, Inc. news